11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Learn More →
Veristat recently participated in the webinar titled "CRO Consolidation: A Sinister Threat or Windfall for Pharma?" View a recording of the webcast now.
With all the recent CRO mergers & acquisitions, a panel of CROs, Sponsors and Patient Advocates discuss the trend and its effects on clinical trial outsourcing. Outsourcing has become a popular way for pharmaceutical companies to utilize on-demand services, improving operational efficiencies and therapeutic expertise and adding extensive geographic capabilities. CROs are growing and acquiring new services and offering to differentiate themselves. So, is this CRO M&A trend good for the pharmaceutical industry as a whole?
In this webinar, a panel of experts representing CROs, Pharma and Patient Advocates will explore the following:
Don't miss your chance to hear Cindy Henderson, Executive Vice President of Strategic Development at Veristat join the conversation in this webinar.
Click Here to sign in and view a recording of the webinar.
11 min read
Oct 21, 2026 Veristat Blog
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
8 min read
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...